Awards & Advancement

Actinium Dr. Mark Berger as chief medical officer

Thursday, January 19, 2017

Actinium Pharmaceuticals, a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced that Dr. Mark Berger has been appointed chief medical officer effective immediately. Dr. Berger joins Actinium with significant drug development expertise that includes the planning and execution of clinical trials that led to the FDA approval of Mylotarg for acute myeloid leukemia (AML) while at Wyeth Research (now Pfizer), and Tykerb for breast cancer while at GlaxoSmithKline. He also has experience in patient care and lab-based cancer research. Dr. Berger will report to Sandesh Seth, Actinium’s executive chairman.

[Read More]

Personal Genome Diagnostics adds James Lewis as SVP of Corporate Development

Thursday, January 19, 2017

Personal Genome Diagnostics (PGDx), a provider of advanced cancer genome testing products and services, has announced that James Lewis has joined the company as senior vice president of Corporate Development. Lewis brings broad biopharmaceutical industry experience to the development and execution of PGDx’s growth strategy. He will oversee strategic planning, collaboration initiatives, and fundraising activities aimed at securing the requisite capital to meet short and long range corporate objectives, including launching a planned series B financing in 2017.

[Read More]

Richard R. Smith joins EMD Serono as SVP and head of US Fertility and Endocrinology

Wednesday, January 18, 2017

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, has announced that Richard R. Smith joined the company as senior vice president and head of U.S. Fertility and Endocrinology. In this role, Mr. Smith will oversee the Fertility and Endocrinology businesses in the U.S., including the U.S. Fertility Technologies division, which launched its first product last year with Gidget, a hand-held witnessing system for the IVF laboratory that provides visual lab workflow management and support for traceability and audit reporting.

[Read More]

Chi-Med appoints Paul Carter to board of directors

Monday, January 16, 2017

Hutchison China MediTech (Chi-Med) has announced, effective from February 1, Paul Rutherford Carter has been appointed as senior independent non-executive director and member of the audit committee, Remuneration Committee and Technical Committee of Chi-Med; and Shigeru Endo tendered his resignation as non-executive director and Christopher Nash tendered his resignation as senior independent non-executive director and member of audit committee and remuneration committee effective on the same date.

[Read More]

Julian Adams joins Vedantra Pharmaceuticals as executive chairman

Thursday, January 12, 2017

Vedantra Pharmaceuticals, an immunotherapy company focused on developing products for cancer and infectious disease, has announced the appointment of Julian Adams, Ph.D., as executive chairman. Dr. Adams, who recently stepped down as president of Research and Development at Infinity Pharmaceuticals, will oversee strategic and operational responsibilities, fund raising and drive R&D program development for the company.

[Read More]

Amplyx appoints Ciara Kennedy president and chief executive officer

Monday, January 9, 2017

Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, has announced the appointments of Ciara Kennedy, Ph.D., to president and chief executive officer (CEO) and Karen Joy Shaw, Ph.D., to chief scientific officer (CSO). In conjunction with this announcement, the company’s former president and CEO, Mike Grey, has assumed the role of executive chairman of the Amplyx board of directors. 

[Read More]